1
|
Badachhape AA, Working PK, Srivastava M, Bhandari P, Stupin IV, Devkota L, Tanifum EA, Annapragada AV, Ghaghada KB. Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease. Sci Rep 2020; 10:16185. [PMID: 32999398 PMCID: PMC7527957 DOI: 10.1038/s41598-020-73233-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 09/09/2020] [Indexed: 01/30/2023] Open
Abstract
In these preclinical studies, we describe ADx-001, an Aβ-targeted liposomal macrocyclic gadolinium (Gd) imaging agent, for MRI of amyloid plaques. The targeting moiety is a novel lipid-PEG conjugated styryl-pyrimidine. An MRI-based contrast agent such as ADx-001 is attractive because of the lack of radioactivity, ease of distribution, long shelf life, and the prevalence of MRI scanners. Dose-ranging efficacy studies were performed on a 1 T MRI scanner using a transgenic APP/PSEN1 mouse model of Alzheimer's disease. ADx-001 was tested at 0.10, 0.15, and 0.20 mmol Gd/kg. Gold standard post-mortem amyloid immunostaining was used for the determination of sensitivity and specificity. ADx-001 toxicity was evaluated in rats and monkeys at doses up to 0.30 mmol Gd/kg. ADx-001 pharmacokinetics were determined in monkeys and its tissue distribution was evaluated in rats. ADx-001-enhanced MRI demonstrated significantly higher (p < 0.05) brain signal enhancement in transgenic mice relative to wild type mice at all dose levels. ADx-001 demonstrated high sensitivity at 0.20 and 0.15 mmol Gd/kg and excellent specificity at all dose levels for in vivo imaging of β amyloid plaques. ADx-001 was well tolerated in rats and monkeys and exhibited the slow clearance from circulation and tissue biodistribution typical of PEGylated nanoparticles.
Collapse
Affiliation(s)
- Andrew A Badachhape
- Department of Radiology, Baylor College of Medicine, Houston, TX, 77030, USA
| | | | - Mayank Srivastava
- The Singleton Department of Pediatric Radiology, Texas Children's Hospital, Houston, TX, 77030, USA
| | - Prajwal Bhandari
- Department of Radiology, Baylor College of Medicine, 1102 Bates Street, Suite 850, Houston, TX, 77030, USA
| | - Igor V Stupin
- The Singleton Department of Pediatric Radiology, Texas Children's Hospital, Houston, TX, 77030, USA
| | - Laxman Devkota
- Department of Pediatrics-Oncology, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Eric A Tanifum
- The Singleton Department of Pediatric Radiology, Texas Children's Hospital, Houston, TX, 77030, USA
| | - Ananth V Annapragada
- The Singleton Department of Pediatric Radiology, Texas Children's Hospital, Houston, TX, 77030, USA
| | - Ketan B Ghaghada
- The Singleton Department of Pediatric Radiology, Texas Children's Hospital, Houston, TX, 77030, USA.
- Department of Radiology, Baylor College of Medicine, 1102 Bates Street, Suite 850, Houston, TX, 77030, USA.
- Edward B. Singleton Department of Radiology, Texas Children's Hospital, Houston, USA.
| |
Collapse
|